Log In


Company Name : Takeda Pharmaceutical Company Limited

Wednesday, January 24, 2018 12:20PM IST (6:50AM GMT)


Takeda Recognized as a Global 100 Most Sustainable Corporation for Third Consecutive Year

Osaka, Japan

Takeda Pharmaceutical Company Limited [TOKYO:4502], (“Takeda”) is proud to be named by Corporate Knights as one of the 2018 Global 100 Most Sustainable Corporations in the World (Global 100) for the third consecutive year. This distinction is based on 17 key performance indicators including financial management, clean revenue, and supplier performance. Takeda performed in the top 25% on innovation capacity, receiving notable recognition for its leadership diversity. Global 100 companies in 2018 represent the top 1.3% in the world on sustainability performance. The Index launched in 2005; results are disclosed annually at the World Economic Forum in Davos.


As a LEAD company within the United Nations Global Compact, Takeda’s established track record in sustainability is guided by long-term international targets such as the Sustainable Development Goals (SDGs). Takeda is the only Japanese pharmaceutical company and among the four companies from Japan to make the final 100 in 2018, and one of just ten pharmaceutical companies in the world to be listed.


“Takeda is honored to be recognized once again for our commitment to sustainability, particularly alongside such distinguished global corporations,” said Haruhiko Hirate, Corporate Communications & Public Affairs Officer. “We strive to create and maximize long-term economic, social, and environmental value worldwide, led by our unique and diverse corporate governance, through our corporate social responsibility (CSR), which contributes to the lasting health of patients worldwide through long-term investments in disease prevention, capacity building, and access to healthcare. As a company, Takeda strives for Better Health and a Brighter Future for people worldwide through leading innovation in medicine, together with the global community.”


In addition to the Global 100 Index, Takeda is recognized by multiple Socially Responsible Investment (SRI) valuations.

Name of Index/Investment


Organization Conducting

  Country   Honors Awarded
Dow Jones Sustainability Asia Pacific Index   S&P Dow Jones Indices   US   8th consecutive year
FTSE4Good Global Index   FTSE Russel   UK   13th consecutive year
Ethibel EXCELLENCE Investment Register   Forum Ethibel   BEL   three times
Prime Status   Oekom   GER   first time

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited (TOKYO:4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.


Additional information about Takeda is available through its Sustainable Value Report, https://www.takeda.com/corporate-responsibility/Sustainable-Value-Report/.





Click here for Media Contact Details

Media Contacts:
Japanese Media
Takeda Pharmaceutical Company Limited
Satoko Imai, +81-3-3278-2037

More News from Takeda Pharmaceutical Company Limited

18/05/2018 2:01PM

Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings

– Data Being Presented Underscore Commitment to Improving Patient Outcomes and Care – – Six Takeda Oncology-Sponsored Abstracts Accepted for Presentation at ASCO 2018 and Eight Abstracts Accepted ...

14/05/2018 7:30PM

Takeda Reports FY2017 Full Year Results and Issues FY2018 Guidance

FY2017 performance reflects superior execution Underlying results: Revenue +5.5%, Core Earnings +40.2%, Core EPS +44.8% Takeda will maintain its underlying growth momentum in FY2018 Takeda Pharmaceutical ...

08/05/2018 1:14PM

Proposed Acquisition of Shire plc by Takeda

– Creates a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan – – Better positions Takeda to deliver highly-innovative medicines and transformative ...

Similar News

25/05/2018 12:18PM

Corporate Social Responsibility Related News Releases and Story Ideas for Reporters, Bloggers and Media Outlets

Following are the latest Corporate Social Responsibility news releases and story ideas available from Business Wire. These recaps, curated by Business Wire, provide reporters and bloggers around the globe instant access ...

No Image

25/05/2018 10:00AM

Chasing a Dream of Inclusive Society - National Organisation for Social Empowerment

India has progressed in every sphere of life including the fields of education, healthcare sector, industrial sector and private sector, but when it comes to providing equal opportunity to poor and downtrodden, we are ...